Literature DB >> 27748737

Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation.

L Castagna1, B Sarina1, R Crocchiolo1, S Bramanti1, S Furst1, R Devillier1, D Coso2, R Bouabdallah2, D Mokart3, L Morabito1, S Harbi1, L Giordano4, A Rimondo1, P Jean Weiller1, C Carlo-Stella1,5, A Santoro1,6, C Chabannon7,8,9, D Blaise1,2,8,9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27748737     DOI： 10.1038/bmt.2016.257

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

1.  Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients.

Authors:  Roberto Crocchiolo; Luca Castagna; Sylvain Garciaz; Sabine Fürst; Jean El Cheikh; Barbara Sarina; Stefania Bramanti; Angela Granata; Andrea Vai; Samia Harbi; Lucio Morabito; Bilal Mohty; Laura Giordano; Raynier Devillier; Diane Coso; Monica Balzarotti; Christian Chabannon; Carmelo Carlo-Stella; Armando Santoro; Reda Bouabdallah; Didier Blaise
Journal:  Haematologica       Date:  2015-07-23       Impact factor: 9.941

2.  Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.

Authors:  Sebastian Theurich; Joke Malcher; Kerstin Wennhold; Alexander Shimabukuro-Vornhagen; Jens Chemnitz; Udo Holtick; Anke Krause; Carsten Kobe; Deniz Kahraman; Andreas Engert; Christof Scheid; Geothy Chakupurakal; Michael Hallek; Michael von Bergwelt-Baildon
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

3.  Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation.

Authors:  Elisa Sala; Roberto Crocchiolo; Sara Gandolfi; Marta Bruno-Ventre; Stefania Bramanti; Jacopo Peccatori; Barbara Sarina; Consuelo Corti; Fabio Ciceri; Armando Santoro; Sarah Marktel; Luca Castagna
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-04       Impact factor: 5.742

4.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

5.  Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.

Authors:  Ron Ram; Ted A Gooley; David G Maloney; Oliver W Press; John M Pagel; Stephen H Petersdorf; Andrei R Shustov; Mary E D Flowers; Paul O'Donnell; Brenda M Sandmaier; Rainer F Storb; Ajay K Gopal
Journal:  Biol Blood Marrow Transplant       Date:  2011-04-12       Impact factor: 5.742

6.  Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.

Authors:  Kitsada Wudhikarn; Claudio G Brunstein; Veronika Bachanova; Linda J Burns; Qing Cao; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2011-02-18       Impact factor: 5.742

7.  Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.

Authors:  Ajay K Gopal; Radhakrishnan Ramchandren; Owen A O'Connor; Robert B Berryman; Ranjana H Advani; Robert Chen; Scott E Smith; Maureen Cooper; Achim Rothe; Jeffrey V Matous; Laurie E Grove; Jasmine Zain
Journal:  Blood       Date:  2012-04-17       Impact factor: 22.113

8.  Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.

Authors:  Jonathan R Lambert; Jamshed B Bomanji; Karl S Peggs; Kirsty J Thomson; Ronjon K Chakraverty; Adele K Fielding; Panagiotis D Kottaridis; Michael Roughton; Emma C Morris; Anthony H Goldstone; David C Linch; Peter J Ell; Stephen Mackinnon
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

9.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

Review 10.  Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.

Authors:  Luca Castagna; Carmelo Carlo-Stella; Rita Mazza; Armando Santoro
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-02-15       Impact factor: 2.576
View more
  2 in total

Review 1.  Beyond CD19 CAR-T cells in lymphoma.

Authors:  Wingchi K Leung; Adanma Ayanambakkam; Helen E Heslop; LaQuisa C Hill
Journal:  Curr Opin Immunol       Date:  2021-11-17       Impact factor: 7.486

2.  Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies.

Authors:  Theodoros Karantanos; Ioannis Politikos; Vassiliki A Boussiotis
Journal:  Blood Lymphat Cancer       Date:  2017-05-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.